Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial
| Autor: | Pieter M. ter Wee, Ilse M. Purmer, S Azam Nurmohamed, Frank H. Bosch, Marc G. Vervloet, Louise Schilder, Cynthia G. Kleppe, A. B. Johan Groeneveld, Armand R. J. Girbes, Sylvia S den Boer, Albertus Beishuizen |
|---|---|
| Přispěvatelé: | Nephrology, Intensive care medicine, ICaR - Circulation and metabolism |
| Rok vydání: | 2014 |
| Předmět: |
Male
medicine.medical_specialty medicine.drug_class medicine.medical_treatment Critical Care and Intensive Care Medicine Citric Acid law.invention Randomized controlled trial law Hemofiltration medicine Humans Renal replacement therapy business.industry Heparin Research Anticoagulant Acute kidney injury Thrombosis Acute Kidney Injury medicine.disease Intensive care unit Discontinuation Surgery Anesthesia Female business medicine.drug |
| Zdroj: | Critical Care Critical Care, 18(4):472. Springer Science + Business Media Schilder, L, Nurmohamed, S A, Bosch, F H, Purmer, I M, den Boer, S S, Kleppe, C G, Vervloet, M G, Beishuizen, A, Girbes, A R J, ter Wee, P M & Groeneveld, A B J 2014, ' Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial ', Critical Care, vol. 18, no. 4, 472 . https://doi.org/10.1186/s13054-014-0472-6 |
| ISSN: | 1466-609X |
| DOI: | 10.1186/s13054-014-0472-6 |
| Popis: | Introduction Because of ongoing controversy, renal and vital outcomes are compared between systemically administered unfractionated heparin and regional anticoagulation with citrate-buffered replacement solution in predilution mode, during continuous venovenous hemofiltration (CVVH) in critically ill patients with acute kidney injury (AKI). Methods In this multi-center randomized controlled trial, patients admitted to the intensive care unit requiring CVVH and meeting inclusion criteria, were randomly assigned to citrate or heparin. Primary endpoints were mortality and renal outcome in intention-to-treat analysis. Secondary endpoints were safety and efficacy. Safety was defined as absence of any adverse event necessitating discontinuation of the assigned anticoagulant. For efficacy, among other parameters, survival times of the first hemofilter were studied. Results Of the 139 patients enrolled, 66 were randomized to citrate and 73 to heparin. Mortality rates at 28 and 90 days did not differ between groups: 22/66 (33%) of citrate-treated patients died versus 25/72 (35%) of heparin-treated patients at 28 days, and 27/65 (42%) of citrate-treated patients died versus 29/69 (42%) of heparin-treated patients at 90 days (P = 1.00 for both). Renal outcome, i.e. independency of renal replacement therapy 28 days after initiation of CVVH in surviving patients, did not differ between groups: 29/43 (67%) in the citrate-treated patients versus 33/47 (70%) in heparin-treated patients (P = 0.82). Heparin was discontinued in 24/73 (33%) of patients whereas citrate was discontinued in 5/66 (8%) of patients (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink